{"id":41982,"date":"2025-08-26T11:44:25","date_gmt":"2025-08-26T10:44:25","guid":{"rendered":"https:\/\/bnssghealthiertogether.org.uk\/?post_type=library&p=41982"},"modified":"2025-08-26T11:44:25","modified_gmt":"2025-08-26T10:44:25","slug":"foi-icb-2526-157-bevacizumab-gamma-lytenava-for-neovascular-wet-age-related-macular-degeneration-nice-ta1022","status":"publish","type":"library","link":"https:\/\/bnssghealthiertogether.org.uk\/ro\/library\/foi-icb-2526-157-bevacizumab-gamma-lytenava-for-neovascular-wet-age-related-macular-degeneration-nice-ta1022\/","title":{"rendered":"FOI.ICB-2526\/157: Bevacizumab Gamma (Lytenava\u00ae) for Neovascular (wet) Age-related Macular Degeneration (NICE TA1022)"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":0,"parent":0,"template":"","categories":[299],"class_list":["post-41982","library","type-library","status-publish","hentry","category-freedom-of-information"],"acf":[],"_links":{"self":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/library\/41982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/library"}],"about":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/types\/library"}],"version-history":[{"count":2,"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/library\/41982\/revisions"}],"predecessor-version":[{"id":41985,"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/library\/41982\/revisions\/41985"}],"wp:attachment":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/media?parent=41982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/categories?post=41982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}